« Back
Home /
Anti-Human IL 12/23 (Briakinumab)

Anti-Human IL 12/23 (Briakinumab)

Item no.	LEIN-LT500-50mg
Manufacturer	Leinco Technologies
Amount	50 mg
Quantity options	1 mg 100 mg 25 mg 5 mg 50 mg Custom
Category	Antibodies Primary Antibodies
Type	Antibody Primary
Applications	WB, FC, IF, IP, ELISA, FA, other
Clone	ABT-874
Specific against	Human (Homo sapiens)
Host	Human
Purity	≥95% monomer by analytical SEC
Citations	1. Vsn, M. et al. (2016) VALUE IN HEALTH 19 PSS5:A123
NCBI	3593
ECLASS 10.1	32160702
ECLASS 11.0	32160702
UNSPSC	12352203
Shipping condition	Cool pack
Available
Manufacturer - Applications	Quality Tested by Leinco FC The suggested concentration for Briakinumab biosimilar antibody for staining cells in flow cytometry is ≤ 0.25 μg per 10⁶ cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
Manufacturer - Category	Recombinant Antibodies>Biosimilar Recombinant Antibodies
Manufacturer - Targets	IL-12/IL-23 p40
Country of Origin	USA
Shipping Temperature	2 - 8°C Wet Ice
Storage Conditions	Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Product Description	Briakinumab is a human monoclonal antibody targets the p40 subunit shared by interleukins 12 and 23. IL-12 associates with IL-23α to form the heterodimeric cytokine IL-23. IL-23 is associated with various autoimmune inflammatory diseases, and is particularly highly expressed in psoriasis skin lesions. In addition, IL-23 is suspected to play a role in tumorigenesis. Briakinumab binds to and neutralizes human IL-12 and IL-23 (via their shared p40 subunit) and is being investigated for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. Anti-Human IL 12/23 (Briakinumab) utilizes the same variable regions from the therapeutic antibody Briakinumab making it ideal for research projects.
Background	Briakinumab is a human monoclonal antibody targets the p40 subunit shared by interleukins 12 and 23. IL-12 associates with IL-23α to form the heterodimeric cytokine IL-23. IL-23 is associated with various autoimmune inflammatory diseases, and is particularly highly expressed in psoriasis skin lesions. In addition, IL-23 is suspected to play a role in tumorigenesis. Briakinumab binds to and neutralizes human IL-12 and IL-23 (via their shared p40 subunit) and is being investigated for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. Anti-Human IL 12/23 (Briakinumab) utilizes the same variable regions from the therapeutic antibody Briakinumab making it ideal for research projects.
Pathogen Testing	To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Other Applications Reported In Literature	B FA WB IP ELISA N IF
PubMed	IL-12/IL-23 p40
Manufacturer - Expression host	HEK-293
Manufacturer - Specificity	This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Briakinumab. Briakinumab recognizes both human IL12 and IL23 via IL-12/23p40. This product is for research use only.
FC Effector Activity	Active
RRID	AB_2893961
Concentration	≥ 5.0 mg/ml
Formulation	This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Product Preparation	Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Antigen Distribution	IL-12 is produced by dendritic cells, macrophages, neutrophils, and human B-lymphoblastoid cells. IL-23 is mainly secreted by activated dendritic cells, macrophages or monocytes.
Immunogen	This antibody was produced by phage display technology.
Regulatory Status	Research Use Only (RUO). Non-Therapeutic.
Additonal Information	Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

LEIN-LT500-50mg-safety-datasheet.pdf